William Edward Boden, MD
May 5th, 2014
Two Experts Look at a Failed HDL Trial
William Edward Boden, MD and Prediman K Shah, MD
William Boden and PK Shah discuss the CHI-SQUARE trial, which failed to show a benefit for an HDL mimetic.
January 27th, 2014
How “Compelling” Are Coronary Anatomy and Ischemic Burden When Considering an Invasive Strategy?
William Edward Boden, MD
William E. Boden discusses his research group’s post hoc analysis of data from the COURAGE trial.
January 9th, 2013
Niacin Therapy in the Crossfire
William Edward Boden, MD and Harlan M. Krumholz, MD, SM
William E. Boden, lead investigator of the AIM-HIGH trial, and CardioExchange’s Harlan M. Krumholz debate the current state of research on niacin therapy.
January 4th, 2013
Why Has Niacin Therapy Failed to THRIVE?
William Edward Boden, MD and John Ryan, MD
In the wake of HPS2-THRIVE, John Ryan asks William E. Boden, lead investigator of the AIM-HIGH trial, for his perspective on niacin and other HDL-modifying therapies.
NEJM Journal Watch — Recent Cardiology Articles- Is Diltiazem Safe in Patients with AF Taking Apixaban or Rivaroxaban?
- Does Lowering High Childhood Lipid Levels Prevent Adverse Cardiovascular Events in Adulthood?
- Self-Expanding Supraannular Valve vs. Balloon-Expandable Valve in TAVR for Small Aortic Annulus
- A New TAVR Prosthesis for Aortic Regurgitation Shows Promise
- Aprocitentan, a Newly Approved Drug for Resistant Hypertension